قالب وردپرس درنا توس
Home / Health / FDA approves $ 2M medicine, most expensive ever

FDA approves $ 2M medicine, most expensive ever



by Linda A. Johnson

 FDA approves $ 2M medicine, most expensive ever
This photo provided by Novartis shows Zolgensma. The one-time gene therapy developed by Novartis, Zolgensma, will cost $ 2,125 million. It treats a rare condition called spinal muscular atrophy, or SMA, which strikes about 400 babies born in the U.S. each year. The therapy, given in a one-hour infusion, is approved for children under age 2 and will be available within two weeks. (Novartis via AP)
            

U.S. regulators have approved the most expensive medicine ever, for a rare disorder that destroys a baby's muscle control and kills nearly all of those with the most common type of the disease within a couple of years.
                                                

The treatment is priced at $ 2,125 million. Out-of-pocket costs for patients vary according to coverage.

The medicine, sold by the Swiss drugmaker Novartis, is a gene therapy of inherited condition called spinal muscular atrophy. The treatment targets are so weak that they become unable to move, and eventually unable to swallow or breathe. It strikes about 400 babies born in the U.S. each year.

The Food and Drug Administration on Friday approved the treatment, called Zolgensma, for all children under age.

Novartis said it will let insurers make payments over five years, at $ 425,000 per year, and will give partial rebates if the treatment does not work.

The one other medicine for the disease approved in the US is a drug called Spinraza. Instead of a one-time treatment, it must be given every four months. Biogen, Spinraza's maker, charges $ 750,000 for the first year and then $ 350,000 per year after that.

The Independent Nonprofit Group Institute for Clinical and Economic Review, which rates the cost of new medicines, calculated that the price

ICER's president, dr. Steven D. Pearson, called the treatment's price. "

Spinal muscular atrophy normally. The nerves off the protein.

 FDA approves $ 2M medicine, most expensive ever
This Aug 13, 2016, file photo shows a logo of Swiss pharmaceutical company Novartis in Seoul, South Korea. On Friday, May 24, 2019, U.S. Pat. Zolgensma, the most expensive medicine ever, is a therapy that usually causes a baby's muscle control and kills within a few years. (AP Photo / Ahn Young-joon, File)
            

In the most common type, which is the most severe, at least 90% of patients by age 2, and any still need a ventilator to breathe.

Zolgensma works by supplying a healthy copy of the faulty gene, which allows nerve cells to start producing the needed protein.

In patients testing, babies with the most severe form of the disease who got Zolgensma within 6 months of birth had limited muscle problems.

Babies given Zolgensma after six months stopped losing muscle control, but the medicine can not reverse damage already done.

It is too early to know how long the benefit of the treatment Lasts, but doctors' hopes are rising. Jerry Mendell, a neurologist at Nationwide Children's in Columbus, Ohio.

"It's beginning to look that way," he said no symptoms.

Early diagnosis is crucial, so Novartis has to be tested with newborns at birth.

The FDA said that the patient has been treated for the first few months after treatment.
                                                                                                                        


Spinal muscular atrophy drug may help children with later-onset disease


© 2019 The Associated Press. All rights reserved.
                                            

Citation :
                                                 FDA approves $ 2M medicine, most expensive ever (2019, May 24)
                                                 retrieved 25 May 2019
                                                 from https://medicalxpress.com/news/2019-05-fda-2m-medicine-expensive.html
                                            

This document is copyrighted. Apart from any fair dealing for the purpose of private study or research, no
                                            part may be reproduced without the written permission. The content is for information purposes only.
                                            


Source link